Vertex Pharmaceuticals Inc (NASDAQ: VRTX) has reported earnings for its first fiscal quarter (ending March 31) of $4.26 versus $2.72 for the same period a year ago — an increase of 57%. However, this result fell short of the consensus estimate of $4.43 by $-0.17. E.P.S. were $15.58 for the latest four quarters through March 31 versus $12.71 for the same period a year ago — an increase of 23%.
Recent Price Action
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock rose modestly by 0.4% on 5/6/24. The stock closed at $402.50. Moreover, this advance was accompanied by above average trading volume at 144% of normal. Relative to the market the stock has been strong over the last nine months and has risen 1.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, VRTX is expected to continue to be an important Value Builder.
Vertex Pharmaceuticals has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Vertex Pharmaceuticals has a neutral Appreciation Score of 54 but a good Power Rating of 72, producing the Positive Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment